Listened to SK presentation. Did not notice mumbling. It definitely could have been slowed and simplified and better tailored for the audience since there was really nothing new, and did represent a "teaching"/sales opportunity. Agree with others here that it was simply an update. It made me think that SK knows that financing is assured through PIII results; that there are other applications for anti-PS than a combination with cytotoxic agents; and that the next big push is combination with immune checkpoint agents.
Some notes (again, nothing new): PPHM has amplified on the finding that -PS inversion on cell membrane is a primary player in immunotherapy. Bavituximab has a good safety profile and significant clnical trial lead over competition in the expanding -PS space. Bavituximab blocks immunosuppression and activates the immune system. Creates a positive tumor microenvironment for other immune checkpoint agents to act more efficiently....changes non-responders into responders. Consistent results in animals and humans with Bavi. 19 studies, 500 patients treated with good saefty profile. Removes the brakes on immune system.
Chemotherapy combos dominate near-term efforts with Bavituximab with current PIII lung cancer study. PIII "well underway". Fast track. Looking beyond, front line lung cancer and breast cancer which have shown initial good results. Combination with Taxanes in breast cancer increases presentation of T cells to tumor Rectal adenocarcinoma and irradiation study looks promising. Melanoma trial. Moving into immunotherapy combination space. Bavi is only "upstream" agent which can combine with any of the many downstream agents. Turning non-responders into responders is a goal, and has been seen consistently. Yervoy trial with melanoma is an example. Possible combination with vaccines.
Avid is profitable. Revenue going into R&D. Nice growth over past several years. Expanding Avid facility for outside orders, Bavi- production, and "other PPHM agents". Several abstracts for ASCO.
question: Discuss evolution of breast indication:
Why move into that crowded space? It has cleared out a bit. More data from Bavi is positive...75% response rate.
question: Lung cancer PII mix-up.
